Cellular and molecular features of COVID-19 associated ARDS: therapeutic relevance.

IF 4.4 3区医学 Q2 IMMUNOLOGY

Journal of Inflammation-London Pub Date : 2023-03-20 DOI:10.1186/s12950-023-00333-2

Gaetano Scaramuzzo, Francesco Nucera, Alessio Asmundo, Roberto Messina, Matilde Mari, Federica Montanaro, Matt D Johansen, Francesco Monaco, Guido Fadda, Giovanni Tuccari, Nicole G Hansbro, Philip M Hansbro, Trevor T Hansel, Ian M Adcock, Antonio David, Paul Kirkham, Gaetano Caramori, Carlo Alberto Volta, Savino Spadaro

引用次数: 0

Abstract

The severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection can be asymptomatic or cause a disease (COVID-19) characterized by different levels of severity. The main cause of severe COVID-19 and death is represented by acute (or acute on chronic) respiratory failure and acute respiratory distress syndrome (ARDS), often requiring hospital admission and ventilator support.The molecular pathogenesis of COVID-19-related ARDS (by now termed c-ARDS) is still poorly understood. In this review we will discuss the genetic susceptibility to COVID-19, the pathogenesis and the local and systemic biomarkers correlated with c-ARDS and the therapeutic options that target the cell signalling pathways of c-ARDS.

Abstract Image

查看原文本刊更多论文

与 COVID-19 相关的 ARDS 的细胞和分子特征：治疗相关性。

严重急性呼吸系统综合征--冠状病毒 2 型（SARS-CoV-2）感染可无症状，也可导致不同严重程度的疾病（COVID-19）。导致严重 COVID-19 和死亡的主要原因是急性（或慢性急性）呼吸衰竭和急性呼吸窘迫综合征（ARDS），通常需要入院治疗和呼吸机支持。在这篇综述中，我们将讨论 COVID-19 的遗传易感性、发病机制、与 c-ARDS 相关的局部和全身生物标志物以及针对 c-ARDS 细胞信号通路的治疗方案。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Inflammation-London IMMUNOLOGY-

CiteScore

7.90

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： Journal of Inflammation welcomes research submissions on all aspects of inflammation. The five classical symptoms of inflammation, namely redness (rubor), swelling (tumour), heat (calor), pain (dolor) and loss of function (functio laesa), are only part of the story. The term inflammation is taken to include the full range of underlying cellular and molecular mechanisms involved, not only in the production of the inflammatory responses but, more importantly in clinical terms, in the healing process as well. Thus the journal covers molecular, cellular, animal and clinical studies, and related aspects of pharmacology, such as anti-inflammatory drug development, trials and therapeutic developments. It also considers publication of negative findings. Journal of Inflammation aims to become the leading online journal on inflammation and, as online journals replace printed ones over the next decade, the main open access inflammation journal. Open access guarantees a larger audience, and thus impact, than any restricted access equivalent, and increasingly so, as the escalating costs of printed journals puts them outside University budgets. The unrestricted access to research findings in inflammation aids in promoting dynamic and productive dialogue between industrial and academic members of the inflammation research community, which plays such an important part in the development of future generations of anti-inflammatory therapies.